Expert Point of View: Next-generation Sequencing in Metastatic Triple-negative Breast Cancer Yields Rewards


Get Permission

3.5.22_rugo.jpgHope Rugo, MD, of the University of California, San Francisco, commented on Dr. O’Shaughnessy’s presentation on molecular pathways in triple-negative breast cancer at the 2011 San Antonio Breast Cancer Symposium. “The really exciting thing is that we have moved from intrinsic subtyping of breast cancer. While this may be important to do in the early setting, when we are looking at metastatic disease we really need to go several steps beyond this and figure out the targets,” she told The ASCO Post

“Dr. O’Shaughnessy’s experience is anecdotal, but it is a window into where we might be able to go from here,” she continued. “Still, we don’t understand enough yet. We cannot make conclusions based on anecdotes or data from single patients. We must be cautious moving forward. We don’t want to do expensive testing on every patient and then have them travel across the country for an experimental trial. But as a research area, this is very exciting.” ■

Disclosure: Dr. Rugo has received research funding from Genentech, Novartis, Merck, and Pfizer.


Related Articles

Next-generation Sequencing in Metastatic Triple-negative Breast Cancer Yields Rewards

The startling molecular heterogeneity of metastatic triple-negative breast cancer is now obvious and helps to explain the poor outcomes observed in this patient subset. Comprehensive genomic and transcriptomic interrogation of metastatic triple-negative breast cancer is elucidating the molecular...

SIDEBAR: Genotype and Treatment Outcomes

At the 2011 San Antonio Breast Cancer Symposium, Joyce O’Shaughnessy, MD, described how the genetic profiles of 12 patients with metastatic triple-negative breast were used to guide treatment for metastatic disease

Patient #10 was a 59-year-old African-American woman with primary...


Advertisement

Advertisement



Advertisement